Closing of Placing of Existing Shares and Top-up Subscription of New Shares under General Mandate

(pdf,147KB)


Next Day Disclosure Return

(pdf,92KB)


Placing of Existing Shares and Top-up Subscription of New Shares under General Mandate

(pdf,68KB)


Ascentage Pharma’s Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

(pdf,184KB)


Ascentage Pharma Delivers Oral Report on the Chinese and
US Studies of Olverembatinib (HQP1351) at 2022 ASH Annual Meeting

(pdf,68KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November

(pdf,64KB)


Ascentage Pharma’s Global Industrial Base Has
Obtained a Production License

(pdf,44KB)


Ascentage Pharma’s Global Industrial Base has
Obtained a Production License

(pdf,64KB)


Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report at the American Association for the Study of Liver Diseases Annual Meeting Showing Potential for Functionally Curing Chronic Hepatitis B

(pdf,64KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October

(pdf,64KB)


Ascentage Pharma is to Present Five Studies of Olverembatinib, APG-2575, and APG-115 at the American Society of Hematology (ASH) Annual Meeting, Four of which have been Selected for Oral Presentations

(pdf,46KB)


Change of Company Email Address

(pdf,46KB)


Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

(pdf,46KB)


Acquisition of Shares by the Chairman and Executive Director

(pdf,46KB)


Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

(pdf,46KB)


Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

(pdf,433KB)


Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

(pdf,433KB)


Purchase of Shares by the Trustee for the Purpose of the 2022 RSU Scheme

(pdf,65KB)


Ascentage Pharma to Announce Results from Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

(pdf,65KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September

(pdf,64KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August

(pdf,67KB)


Announcement of Unaudited Interim Results for the Six Months Ended June 30, 2022

(pdf,1.2MB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July

(pdf,66KB)


(1) Change of Principal Place of Business in HONG KONG and (2) Change of Address of HONG KONG BRANCH Share Registrar and Transfer Office

(pdf,431KB)


Study of Ascentage Pharma’s Olverembatinib Approved in Canada

(pdf,74KB)


Ascentage Pharma Announces that the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML

(pdf,74KB)


Supplemental Announcement(1) Adoption of the 2022 RSU Scheme; and
(2) Initial Grant of Awards under the 2022 RSU Scheme

(pdf,429KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June

(pdf,67KB)


Ascentage Pharma’s Novel Potent EED Inhibitor APG-5918 Obtained IND Clearance by the US FDA and will launch First-in-Human Study

(pdf,438KB)


(1) Adoption of the 2022 RSU Scheme; and (2) Initial Grant of Awards under the 2022 RSU Scheme

(pdf,472KB)


Ascentage Pharma Releases Encouraging Clinical Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphomas

(pdf,442KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May

(pdf,467KB)


2021 Environmental, Social and Governance Report

(pdf,5MB)


Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development

(pdf,467KB)


Ascentage Pharma to Present Latest Clinical Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas at 2022 European Hematology Association Hybrid Congress

(pdf,440KB)


(1) Poll Results of the Annual General Meeting Held on MAY 19, 2022; (2) Resignation of Non-executive Directors; (3) Change in Composition of the Remuneration Committee; and (4) Amendments to Memorandum and Articles of Association

(pdf,448KB)


The Companies Act(As Amended) Company Limited by Shares Second Amended and Restated Memorandum and Articles of Association of Ascentage Pharma Group international

(pdf,688KB)


Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib’s Therapeutic Potential in Treating COVID-19 Published
in EMBO Molecular Medicine

(pdf,444KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April

(pdf,67KB)


Resubmission of Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March

(pdf,67KB)


Ascentage to Present Data from Seven Clinical Studies at ASCO 2022

(pdf,440KB)


Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

(pdf,64KB)


Notice of Annual General Meeting

(pdf,64KB)


Proposed Re-election of Retiring Directors, Proposed Granting of General Mandates to Issue Shares and Repurchase Shares, Proposed Amendments to the Memorandum and Articles of Association and Notice of Annual General Meeting

(pdf,64KB)


Form of Proxy for the Annual General Meeting to be Held on MAY 19, 2022

(pdf,64KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March

(pdf,64KB)


Ascentage Pharma’s MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma

(pdf,428KB)


Proposed Amendments to the Amended and Restated Memorandum and Articles of Association

(pdf,428KB)


ANNOUNCEMENT OF ANNUAL RESULTS
FOR THE YEAR ENDED DECEMBER 31, 2021

(pdf,893KB)


Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Bcl-2 Selective Inhibitor Lisaftoclax (APG-2575) for the Treatment of R/R CLL/SLL

(pdf,428KB)


Notice of Board Meeting

(pdf,428KB)


Ascentage Pharma to Present Latest Results from Six Preclinical Studies at American Association for Cancer Research (AACR) Annual Meeting 2022

(pdf,65KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February

(pdf,65KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January

(pdf,65KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December

(pdf,65KB)


Ascentage Pharma Presents Results of Six Studies of Three Novel Drug Candidates under Development (Olverembatinib, APG-2575, and APG-1252) at the 63rd American Society of Hematology (ASH)
Annual Meeting

(pdf,466KB)


Ascentage Pharma Announces CDE’s Approval for the Phase II Pivotal Study in
China of the Bcl-2 Inhibitor Lisaftoclax (APG-2575) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

(pdf,438KB)


Ascentage Pharma and Clover Enter into Clinical Collaboration to Jointly Develop IAP Antagonist, APG-1387, in Combination with Recombinant Human TRIAL-Trimer Fusion Protein, SCB-313,for the Treatment of Peritoneal Carcinomatosis

(pdf,74KB)


Next Day Disclosure Return

(pdf,86KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November

(pdf,66KB)


Appointment of Chief Financial Officer

(pdf,455KB)


Ascentage Pharma Announces Approval by NMPA for China’s First Approved Third-Generation
BCR-ABL TKI HQP1351 (Olverembatinib)

(pdf,455KB)


Ascentage Pharma’s core drug candidate HQP1351 (Olverembatinib) Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia

(pdf,449KB)


On-market Repurchase of Shares

(pdf,434KB)


Next Day Disclosure Return

(pdf,86KB)


On-market Repurchase of Shares

(pdf,434KB)


Next Day Disclosure Return

(pdf,87KB)


On-market Repurchase of Shares

(pdf,434KB)


Next Day Disclosure Return

(pdf,86KB)


Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in the Treatment of Metastatic ER+/HER2- Breast Cancer

(pdf,475KB)


On-market Repurchase of Shares

(pdf,434KB)


Next Day Disclosure Return

(pdf,86KB)


On-market Repurchase of Shares

(pdf,475KB)


Next Day Disclosure Return

(pdf,32KB)


Abstracts on six studies of Ascentage Pharma’s three drug candidates under development (Olverembatinib, APG-2575, and APG-1252) have been
selected for oral presentation and poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting

(pdf,475KB)


Next Day Disclosure Return

(pdf,87KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October

(pdf,61KB)


On-market Repurchase of Shares

(pdf,434KB)


Resignation of Chief Financial Officer

(pdf,429KB)


Completion of the Issuance of Unlisted Warrants under Specific Mandate

(pdf,74KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September

(pdf,63KB)


Ascentage Pharma’s MDM2-p53 Inhibitor APG-115 Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma

(pdf,441KB)


Poll Results of the Extraordinary General Meeting Held on September 20,2021

(pdf,438KB)


(1) Disclosable Transactions — Subscription of Commercial Paper and Structured Financial Products and (2) Supplemental Announcement in relation to the 2021 Interim Report

(pdf,114KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August

(pdf,63KB)


Form of Proxy for the Extraordinary General Meeting to be Held on September 20, 2021

(pdf,589KB)


Notice Of Extraordinary General Meeting

(pdf,82KB)


Circular (1) Connected Transaction — Proposed Grant of RSUs to Connected Selected Persons;(2) Proposed Grant of RSU Specific Mandate to Issue Shares under the 2021 RSU scheme; (3) Proposed Grant of Warrant Specific Mandate to Issue Unlisted Warrants and Warrant Shares and (4) Notice of Extraordinary General Meeting

(pdf,1MB)


Retirement of Chief Operating Officer

(pdf,61KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July(Revised)

(pdf,64KB)


Announcement of Unaudited Interim Results for the Six Months Ended JUNE 30, 2021

(pdf,437KB)


Notice of Board Meeting

(pdf,57KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July

(pdf,984KB)


Delay in Despatch of Circular in relation to (1) Proposed Issuance of Unlisted Warrants under Specific Mandate; and (2) Connected Trsansactions — Proposed Grant of Awards under the 2021 RSU Scheme to Independent Non-executive Directors and Chief Commercial Officer

(pdf,433KB)


Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325

(pdf,440KB)


Connected Transaction Cancellation of Proposed Grant of Awards and Proposed Re-grant of Awards under the 2021 RSU Scheme to independent non-executive Directors

(pdf,446KB)


Next Day Disclosure Return

(pdf,32KB)


Ascentage Pharma’s MDM2-p53 Inhibitor, APG-115 (Alrizomadlin), Received an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma

(pdf,446KB)


Ascentage Pharma Establishes Cooperation with the US National Cancer Institute to advance the Clinical Development of Ascentage Pharma’s Bcl-2/Bcl-xL inhibitor APG-1252

(pdf,441KB)


Inside Information – Entry Into of the HQP1351 Collaboration and License agreement and the APG2575 Combination Therapy Strategic Collaboration and Clinical Trial Agreement; Issuance of New Shares under General Mandate; and Proposed Issuance of Unlisted Warrants under Specific Mandate

(pdf,159KB)


Connected Transaction Proposed Grant of Awards under the 2021 RSU Scheme to Independent Non-executive Directors Appointment of Independent Financial Adviser

(pdf,446KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June

(pdf,278KB)


Next Day Disclosure Return

(pdf,169KB)


2020 Environmental, Social and Governance Report

(pdf,5MB)


CLARIFICATION ANNOUNCEMENT GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO THE INDEPENDENT SELECTED PERSONS

(pdf,433KB)


UPDATE ANNOUNCEMENT GRANT OF AWARDS UNDE